Abstract
The ROSE-AHF study was a double-blind, randomized, placebo controlled trial designed to determine whether (1) low dose dopamine (2 ug/kg/min); or (2) low dose nesiritide (0.005 ug/kg/min without bolus) were superior to placebo in enhancing decongestion and preserving renal function during diuretic therapy in patients with acute heart failure (AHF) and renal dysfunction. The primary results of the ROSE-AHF study demonstrated that overall, neither active therapy was superior to placebo in enhancing decongestion or preserving renal function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
